{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:18:46Z","timestamp":1789647526953,"version":"4.0.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Infections caused by carbapenem-resistant\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      (CRPA) are related to higher mortality. The objective of this study was to explore clinical outcomes of CRPA bacteremia, identify risk factors and also, compare the efficacy of traditional and novel antibiotic regimens.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study was conducted at a blood diseases hospital in China. The study included hematological patients who were diagnosed with CRPA bacteremia between January 2014 and August 2022. The primary endpoint was all-cause mortality at day 30. Secondary endpoints included 7-day and 30-day clinical cure. Multivariable Cox regression analysis was employed to identify mortality-related risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      100 patients infected with CRPA bacteremia were included and 29 patients accepted allogenic-hematopoietic stem cell transplantation. 24 received ceftazidime-avibactam (CAZ-AVI)-based therapy and 76 received other traditional antibiotics. 30-day mortality was 21.0%. Multivariable cox regression analysis showed neutropenia &amp;gt;7 days after bloodstream infections (BSI) (P=0.030, HR: 4.068, 95%CI: 1.146~14.434), higher Pitt bacteremia score (P&amp;lt;0.001, HR:1.824, 95%CI: 1.322~2.517), higher Charlson comorbidity index (P=0.01, HR: 1.613, 95%CI: 1.124~2.315) and bacteremia due to multidrug-resistant\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      (MDR-PA) (P=0.024, HR:3.086, 95%CI: 1.163~8.197) were identified as independent risk factors of 30-day mortality. After controlling for confounders, an additional multivariable cox regression analysis revealed definitive regimens containing CAZ-AVI were associated with lower mortality in CRPA bacteremia (P=0.016, HR: 0.150, 95%CI: 0.032~0.702), as well as in MDR-PA bacteremia (P=0.019, HR: 0.119, 95%CI: 0.020~0.709).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For patients with hematological diseases and CRPA bacteremia, 30-day mortality rate was 21.0% (21\/100). Neutropenia &amp;gt;7 days after BSI, higher Pitt bacteremia score, higher Charlson comorbidity index and bacteremia due to MDR-PA increased 30-day mortality. CAZ-AVI-based regimens were effective alternatives for bacteremia due to CRPA or MDR-PA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2023.1156651","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T04:19:33Z","timestamp":1687321173000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa in patients with hematological diseases"],"prefix":"10.3389","volume":"13","author":[{"given":"Sisi","family":"Zhen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengkui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02292-21","article-title":"Real-life use of Ceftolozane\/Tazobactam for the treatment of bloodstream infection due to pseudomonas aeruginosa in neutropenic hematologic patients: a matched control study (ZENITH study)","volume":"10","author":"Bergas","year":"2022","journal-title":"Microbiol. Spectrum."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01243-16","article-title":"Carbapenem-resistant pseudomonas aeruginosa bacteremia: risk factors for mortality and microbiologic treatment failure","volume":"61","author":"Buehrle","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1128\/aac.01190-09","article-title":"Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against klebsiella pneumoniae producing the KPC carbapenemase versus that against pseudomonas aeruginosa in an in vitro pharmacodynamic model","volume":"54","author":"Bulik","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2147\/idr.S350976","article-title":"Pseudomonas aeruginosaCeftazidime\/Avibactam versus polymyxin b in the challenge of carbapenem-resistant infection","volume":"15","author":"Chen","year":"2022","journal-title":"Infection Drug Resistance."},{"key":"B5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ajic.2018.10.025","article-title":"The impact of carbapenem-resistant pseudomonas aeruginosa on clinical and economic outcomes in a Chinese tertiary care hospital: a propensity score-matched analysis","volume":"47","author":"Chen","year":"2019","journal-title":"Am. J. Infect. Control."},{"key":"B6","unstructured":"Wayne, PAClinical and Laboratory Standards InstitutePerformance standards for antimicrobial susceptibility testing, M1002021"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1093\/jac\/dkaa267","article-title":"Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study","volume":"75","author":"Cojutti","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106517","article-title":"Effectiveness of ceftazidime-avibactam for the treatment of infections due to pseudomonas aeruginosa","volume":"59","author":"Corbella","year":"2022","journal-title":"Int. J. Antimicrob. Agents."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1099\/jmm.0.073262-0","article-title":"Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome","volume":"63","author":"Dantas","year":"2014","journal-title":"J. Med. Microbiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1086\/344653","article-title":"Prevention of resistance: a goal for dose selection for antimicrobial agents","volume":"36","author":"Drusano","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ijantimicag.2013.09.002","article-title":"Combination antibiotic therapy versus monotherapy for pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies","volume":"42","author":"Hu","year":"2013","journal-title":"Int. J. Antimicrob. Agents."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1128\/aac.04166-14","article-title":"Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units","volume":"59","author":"Jaruratanasirikul","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.diagmicrobio.2014.07.003","article-title":"Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant pseudomonas aeruginosa: clinical impact of bacterial virulence and strains on outcome","volume":"80","author":"Jeong","year":"2014","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/mdr.2010.0170","article-title":"Risk factors for mortality in patients with pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome","volume":"17","author":"Joo","year":"2011","journal-title":"Microbial Drug Resistance"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz522","article-title":"Real-world experience with ceftazidime-avibactam for multidrug-resistant gram-negative bacterial infections","volume":"6","author":"Jorgensen","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-Treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin. Infect. Dis. an Off. Publ. Infect. Dis. Soc. America."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-161","article-title":"Risk factors for mortality in patients with pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy","volume":"14","author":"Kim","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1177\/0091270003257225","article-title":"Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem","volume":"43","author":"Kuti","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1128\/cmr.00040-09","article-title":"Antibacterial-resistant pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40121-021-00570-z","article-title":"Aminoglycoside or polymyxin monotherapy for treating complicated urinary tract infections caused by extensively drug-resistant pseudomonas aeruginosa: a propensity score-adjusted and matched cohort study","volume":"11","author":"L\u00f3pez Montesinos","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"B22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/23744235.2017.1411605","article-title":"Combination antibiotic therapy for pseudomonas aeruginosa bacteremia in febrile neutropenic patients? the question still remains","volume":"50","author":"McCarthy","year":"2018","journal-title":"Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1099\/jmm.0.000538","article-title":"Pseudomonas aeruginosaRisk factors and predictors of carbapenem-resistant and mortality in critically ill bacteraemic patients over a 6-year period (2010-15): antibiotics do matter","volume":"66","author":"Papadimitriou-Olivgeris","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1128\/aac.05991-11","article-title":"Prospective multicenter study of the impact of carbapenem resistance on mortality in pseudomonas aeruginosa bloodstream infections","volume":"56","author":"Pe\u00f1a","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/cid\/cit223","article-title":"Effect of adequate single-drug vs combination antimicrobial therapy on mortality in pseudomonas aeruginosa bloodstream infections: a post hoc analysis of a prospective cohort","volume":"57","author":"Pe\u00f1a","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","article-title":"Multiplex PCR for detection of acquired carbapenemase genes","volume":"70","author":"Poirel","year":"2011","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/s2666-5247(22)00329-9","article-title":"Global epidemiology and clinical outcomes of carbapenem-resistant pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study","volume":"4","author":"Reyes","year":"2023","journal-title":"Lancet Microbe"},{"key":"B28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13756-019-0520-8","article-title":"A retrospective analysis of pseudomonas aeruginosa bloodstream infections: prevalence, risk factors, and outcome in carbapenem-susceptible and -non-susceptible infections","volume":"8","author":"Shi","year":"2019","journal-title":"Antimicrob. Resist. Infect. Control."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02777","article-title":"Is meropenem as a monotherapy truly incompetent for meropenem-nonsusceptible bacterial strains? a Pharmacokinetic\/Pharmacodynamic modeling with Monte Carlo simulation","volume":"10","author":"Song","year":"2019","journal-title":"Front. Microbiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1128\/aac.00207-10","article-title":"Impact of multidrug-resistant pseudomonas aeruginosa bacteremia on patient outcomes","volume":"54","author":"Tam","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious diseases society of America guidance on the treatment of extended-spectrum \u03b2-lactamase producing enterobacterales (ESBL-e), carbapenem-resistant enterobacterales (CRE), and pseudomonas aeruginosa with difficult-to-Treat resistance (DTR-p. aeruginosa)","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/22221751.2022.2048972","article-title":"Carbapenemase-producing pseudomonas aeruginosa -an emerging challenge","volume":"11","author":"Tenover","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"B33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00281-011-0300-x","article-title":"Colonization, pathogenicity, host susceptibility, and therapeutics for staphylococcus aureus: what is the clinical relevance","volume":"34","author":"Tong","year":"2012","journal-title":"Semin. Immunopathol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/antibiotics9020071","article-title":"EnterobacteralesClinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant gram-negative bacteria other than carbapenem-resistant","volume":"9","author":"Vena","year":"2020","journal-title":"Antibiotics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cmi.2019.07.002","article-title":"Predictors of multidrug-resistant pseudomonas aeruginosa in neutropenic patients with bloodstream infection","volume":"26","author":"Viasus","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2016.22","article-title":"Mortality attributable to carbapenem-resistant pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies","volume":"5","author":"Zhang","year":"2016","journal-title":"Emerg. Microbes Infect."},{"key":"B37","doi-asserted-by":"publisher","first-page":"S386","DOI":"10.1093\/cid\/ciaa1522","article-title":"Risk factors and outcomes of antibiotic-resistant pseudomonas aeruginosa bloodstream infection in adult patients with acute leukemia","volume":"71","author":"Zhao","year":"2020","journal-title":"Clin. Infect. Dis. an Off. Publ. Infect. Dis. Soc. America."},{"key":"B38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jinf.2022.08.037","article-title":"Pseudomonas aeruginosa bloodstream infection in patients with hematological diseases: clinical outcomes and prediction model of multidrug-resistant infections","volume":"86","author":"Zhao","year":"2022","journal-title":"J. Infect"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1156651\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T04:19:38Z","timestamp":1687321178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1156651\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":38,"alternative-id":["10.3389\/fcimb.2023.1156651"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1156651","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"article-number":"1156651"}}